Predictors of Poor Prognosis in HFpEF
ConditionHFpEF
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation
About this trial
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
Eligibility criteria
Qualifiers
Signed and data informed consent;
New York Heart Association (NYHA) class II-III heart failure;
Left ventricular ejection fraction > 50%;
Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.
Disqualifiers
Evidence of myocardial ischemia during stress echocardiography;
Significant lesions of the main coronary arteries;
Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);
Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov